Search Page

1

Cite

Share

Circulating tumor cells: a multifunctional biomarker.

Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Yap TA, et al. Among authors: olmos d. Clin Cancer Res. 2014 May 15;20(10):2553-68. doi: 10.1158/1078-0432.CCR-13-2664. Clin Cancer Res. 2014. PMID: 24831278 Review.

Cite

Share

2

Cite

Share

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.

Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: olmos d. Br J Cancer. 2008 Mar 25;98(6):1029-33. doi: 10.1038/sj.bjc.6604218. Epub 2008 Mar 18. Br J Cancer. 2008. PMID: 18349817 Free PMC article.

Cite

Share

3

Cite

Share

Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.

Attard G, Ang JE, Olmos D, de Bono JS. Attard G, et al. Among authors: olmos d. J Clin Pathol. 2008 Aug;61(8):891-6. doi: 10.1136/jcp.2008.056341. Epub 2008 May 21. J Clin Pathol. 2008. PMID: 18495790 Review.

Cite

Share

4

Cite

Share

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS. Olmos D, et al. Ann Oncol. 2009 Jan;20(1):27-33. doi: 10.1093/annonc/mdn544. Epub 2008 Aug 11. Ann Oncol. 2009. PMID: 18695026 Free article.

Cite

Share

5

Cite

Share

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS. Ang JE, et al. Among authors: olmos d. Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Br J Cancer. 2009. PMID: 19223900 Free PMC article. Review.

Cite

Share

6

Cite

Share

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.

Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: olmos d. J Clin Oncol. 2009 Jun 1;27(16):2692-6. doi: 10.1200/JCO.2008.19.5081. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332724

Cite

Share

7

Cite

Share

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. Attard G, et al. Among authors: olmos d. Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667. Cancer Res. 2009. PMID: 19339269 Free article.

Cite

Share

8

Cite

Share

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Postel-Vinay S, Arkenau HT, Olmos D, Ang J, Barriuso J, Ashley S, Banerji U, De-Bono J, Judson I, Kaye S. Postel-Vinay S, et al. Among authors: olmos d. Br J Cancer. 2009 May 5;100(9):1373-8. doi: 10.1038/sj.bjc.6605030. Br J Cancer. 2009. PMID: 19401696 Free PMC article.

Cite

Share

9

Cite

Share

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Attard G, et al. Among authors: olmos d. J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470933 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS. Attard G, et al. Among authors: olmos d. Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Cancer Res. 2009. PMID: 19509232 Review.

Cite

Share